The market for 'ed tech' will grow some 1.4 times from fiscal 2021 to ¥362.5 billion in fiscal 2027, Nomura Research ...

Japan's land and infrastructure ministry has showcased the trial use of remote-controlled heavy equipment, developed in Japan ...

On Thursday, the Japan Ministry of Health, Labour and Welfare approved SIGA Technologies (NASDAQ:SIGA) antiviral treatment TEPOXX (tecovirimat 200 mg capsules) for smallpox, mpox, cowpox, as well as ...

DENSO will showcase its latest technologies at the Japan Mobility Show 2025, scheduled from Oct. 30 to Nov. 9 at Tokyo Big ...

Japan’s lunar achievement isn’t only symbolic—Japan is demonstrating a number of new technologies with its Smart Lander. Japan landed its Smart Lander for Investigating the Moon, or SLIM, craft on the ...

TOKYO (Reuters) - Japanese Prime Minister Fumio Kishida plans to discuss energy markets on a trip to Saudi Arabia, United Arab Emirates and Qatar later this month, aiming to offer Japanese ...

SIGA Technologies has announced that its antiviral treatment, TEPOXX (tecovirimat), has received regulatory approval in Japan for treating orthopoxviruses such as smallpox, mpox, and cowpox, along ...

Every time Bella publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from ...

Belgium-based microelectronics research hub Imec has signed a Memorandum of Cooperation (MOC) with Japan's newly formed semiconductor champion Rapidus Corp. Rapidus was formed in November, backed by ...

Balanced precariously on the Pacific Ocean’s volcanic “Rim of Fire” and constantly at the mercy of powerful weather systems, Japan faces one of the most challenging natural environments in the world.

Global X Japan sold 15,730 shares of Palantir Technologies, with an estimated transaction value of ~$2.55 million based on the average closing price for the quarter. On October 15, 2025, Global X ...

Japan approves SIGA's TEPOXX, the first antiviral for orthopoxviruses, for smallpox, mpox, cowpox, and vaccine-related complications. Approval is based on 15 clinical trials and pivotal animal studies ...